198 related articles for article (PubMed ID: 37675556)
1. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
[TBL] [Abstract][Full Text] [Related]
2. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
3. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
4. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
5. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
6. HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation.
Klobuch S; Hammon K; Vatter-Leising S; Neidlinger E; Zwerger M; Wandel A; Neuber LM; Heilmeier B; Fichtner R; Mirbeth C; Herr W; Thomas S
Cells; 2020 May; 9(5):. PubMed ID: 32443793
[TBL] [Abstract][Full Text] [Related]
7. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
8. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
[TBL] [Abstract][Full Text] [Related]
9. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
11. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
[TBL] [Abstract][Full Text] [Related]
13. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
[TBL] [Abstract][Full Text] [Related]
15. Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.
Holler A; Zech M; Ghorashian S; Pike R; Hotblack A; Veliça P; Xue SA; Chakraverty R; Morris EC; Stauss HJ
Haematologica; 2016 Apr; 101(4):482-90. PubMed ID: 26802053
[TBL] [Abstract][Full Text] [Related]
16. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
19. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Degagné É; Donohoue PD; Roy S; Scherer J; Fowler TW; Davis RT; Reyes GA; Kwong G; Stanaway M; Larroca Vicena V; Mutha D; Guo R; Edwards L; Schilling B; Shaw M; Smith SC; Kohrs B; Kufeldt HJ; Churchward G; Ruan F; Nyer DB; McSweeney K; Irby MJ; Fuller CK; Banh L; Toh MS; Thompson M; Owen ALG; An Z; Gradia S; Skoble J; Bryan M; Garner E; Kanner SB
Cancer Immunol Res; 2024 Apr; 12(4):462-477. PubMed ID: 38345397
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.
Miyazaki Y; Fujiwara H; Asai H; Ochi F; Ochi T; Azuma T; Ishida T; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2013 Jun; 121(24):4894-901. PubMed ID: 23641014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
